Jul. 15 at 10:09 PM
$VRNO - justify loosening federal restrictions. Notably, during cross-examination by the DEA, leading prohibitionist Smart Approaches to Marijuana’s witness, Dr. Bertha Madras—a Harvard Professor of Psychobiology—acknowledged that cannabis meets the statutory criteria for Schedule III. Meanwhile, two medical cannabis companies moved to intervene in consolidated federal D.C. Circuit lawsuits challenging the U.S. Attorney General’s April 28 Final Order—which has already transferred cannabis subject to state medical cannabis licensing to Schedule III—arguing they would suffer direct economic and operational harm if opponents succeed in blocking the reform and that the government cannot adequately represent their interests alone. In addition, DEA has recently filed its opposition to certain rescheduling opponents’ motion for a stay of medical cannabis rescheduling, arguing that petitioners lack standing and, moreover, their “pocketbook interests” make them unsuitable challengers of
